None have been approved by the Food and Drug Administration so far, though in 2019, Johnson & Johnson received FDA permission ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

In just over five minutes, Johnson & Johnson tackles the complicated nature of living with depression — both from the perspective of patients and caregivers — in a recently released short film.

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of ...

On Friday, Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The ...

While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to ...

Johnson & Johnson’s other depression drug Spravato (esketamine), in January, received FDA approval as the only monotherapy for adults living with major depressive disorder who have had an ...

On Friday, Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment ...